Next Article in Journal
Characterization of the Burkholderia cenocepacia TonB Mutant as a Potential Live Attenuated Vaccine
Previous Article in Journal
Newcastle Disease Virus Vectored Bivalent Vaccine against Virulent Infectious Bursal Disease and Newcastle Disease of Chickens
Article Menu

Export Article

Open AccessArticle
Vaccines 2017, 5(4), 32; doi:10.3390/vaccines5040032

Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria

1
Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), The Jenner Institute, University of Oxford, Oxford OX3 7BN, UK
2
Allergy Therapeutics (UK) Ltd. Dominion Way, Worthing BN14 8SA, UK
3
Bencard Allergie GmbH, Leopoldstr, 175, 80804 München, Germany
4
Immunology, RIA, Inselspital, University of Bern, 3010 Bern ,Switzerland
*
Authors to whom correspondence should be addressed.
Academic Editor: Shiladitya DasSarma
Received: 12 July 2017 / Revised: 25 August 2017 / Accepted: 20 September 2017 / Published: 27 September 2017
View Full-Text   |   Download PDF [3002 KB, uploaded 29 September 2017]   |  

Abstract

Microcrystalline Tyrosine (MCT®) is a widely used proprietary depot excipient in specific immunotherapy for allergy. In the current study we assessed the potential of MCT to serve as an adjuvant in the development of a vaccine against malaria. To this end, we formulated the circumsporozoite protein (CSP) of P. vivax in MCT and compared the induced immune responses to CSP formulated in PBS or Alum. Both MCT and Alum strongly increased immunogenicity of CSP compared to PBS in both C57BL/6 and BALB/c mice. Challenge studies in mice using a chimeric P. bergei expressing CSP of P. vivax demonstrated clinically improved symptoms of malaria with CSP formulated in both MCT and Alum; protection was, however, more pronounced if CSP was formulated in MCT. Hence, MCT may be an attractive biodegradable adjuvant useful for the development of novel prophylactic vaccines. View Full-Text
Keywords: vaccine; malaria; adjuvant; MCT vaccine; malaria; adjuvant; MCT
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Cabral-Miranda, G.; Heath, M.D.; Gomes, A.C.; Mohsen, M.O.; Montoya-Diaz, E.; Salman, A.M.; Atcheson, E.; Skinner, M.A.; Kramer, M.F.; Reyes-Sandoval, A.; Bachmann, M.F. Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria. Vaccines 2017, 5, 32.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top